Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2016

View Archived Issues

EMA committee hands down positive opinion on Arzerra for relapsed CLL

Eagle Pharmaceuticals to acquire Arsia Therapeutics

European approval for Parsabiv to treat secondary hyperparathyroidism in hemodialysis patients

Combining Cas9 RNP with ssODN mediates efficient HSPC genome editing of sickle mutation

Eagle Pharmaceuticals initiates rolling NDA for Ryanodex in EHS

EMA adopts positive opinion for Novo Nordisk's Fiasp

EMA gives positive opinion on Gilead's MAA for Vemlidy

Ultragenyx Pharmaceutical withdraws conditional MAA from the EMA for Ace-ER

Recent Esteve patent describes sigma1 receptor ligands for pain

Harvard College reports insulin-degrading enzyme inhibitors

Constellation Pharmaceuticals prepares and tests LSD1 inhibitors

The Vanderbilt University discloses M1 receptor PAMs

Medshine Discovery presents JAK2 inhibitors

Interim phase I/II data presented on combination of lirilumab and nivolumab in head & neck cancer

Novel nanomedicine with alendronic acid corona shows promise for treatment of osteosarcoma

EMA's CHMP recommends approval of Suliqua

European Commission approves use of ustekinumab for Crohn's disease

Promising phase III topline results for CAM-2038 to treat moderate to severe opioid use disorder

Immune activation seen with CD122-biased cytokine NKTR-214 in cancer patients

OncBioMune updates progress in acquisition of Vitel Laboratorios

Blockade of H1R and H4R has additive effects in suppressing peanut-induced intestinal anaphylaxis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...